CTOs on the Move

Halozyme

www.halozyme.com

 
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients` lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme`s commercially-validated solution has touched more than 500,000 patient lives in post-marketing use via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs ...
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.halozyme.com
  • 11388 Sorrento Valley Road
    San Diego, CA USA 92121
  • Phone: 858.794.8889

Executives

Name Title Contact Details
Richa Krishnanand
Senior Director of Technology, Enterprise Analytics and Artificial Intelligence Profile
Cliff Johns
Senior Director, Information Technology Profile

Funding

Halozyme raised $30M on 02/06/2019
Halozyme raised $15M on 05/14/2020

Similar Companies

Viridian Therapeutics

Viridian Therapeutics focuses in advancing new treatments for patients with diseases that are underserved by today`s therapies.

Celsis Inc

Celsis Inc is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elicio

Elicio is committed to transforming the lives of patients and their families by re-engineering the body`s immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body`s own system of defenses, to defeat cancer and stop its recurrence. This substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. Elicio`s lead Amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed in the labs of Darrell Irvine Ph.D., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator, at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. Preclinical studies have demonstrated that Elicio`s Amphiphile vaccines target and concentrate in the lymph nodes resulting in unprecedented tumor-specific immune responses and durable cures of aggressive tumor models in mice.

Pharma-Bio Serv

Pharma-Bio Serv is a Plymouth Meeting, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LEXEO Therapeutics

LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic and acquired diseases.